Advertisement

Arsenal Medical receives a $15.5 million Phase II contract from DARPA to support the company's foam-based intra-abdominal hemorrhage control product for soldiers injured on the battlefield.

Arsenal Medical logo

Watertown, Mass.-based Arsenal Medical received a $15.5 million Phase II contract from the Defense Advanced Research Projects Agency to support its wound management product.

The foam-based product could help combat medics control hemorrhaging in the intact abdominal cavity and reduce battlefield mortality, a large percentage of which is caused by internal bleeding from abdominal injuries, according to a press release.

The new DARPA funding, which is intended to support the product's late-stage development and a regulatory submission, brings Arsenal's total DARPA awards to $22.5 million, the company said.

Advertisement
Advertisement